Therapeutics

Displaying 21 - 25 of 25


Treating Glioblastoma by a Combination Therapy of Gamma-secretase inhibitors and Farnesyltransferase Inhibitors

Scientists at Vanderbilt have developed a novel therapy for gliobastoma multiform that results in minimal recurrence of the tumor. The therapy combines two inhibitors that effectively compromise tumor cell growth and survival. The therapy can be followed by radiation, a common treatment for cancer cells.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Jialiang Wang
Therapeutics

Micro and NanoParticulate Polymeric Delivery System

The present invention provides a method of making particles useful in drug delivery, comprising the steps of: contacting polyanionic polymers with cations in a stirred reactor so that polyanions and the cations react to form particles.


Licensing Contact

Taylor Jordan

615.936.7505

Inventors

Ales Prokop
Therapeutics

Use of mGluR5 Partial Antagonists for the Treatment of Anxiety and Other CNS Disorders

Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.


Licensing Contact

Tom Utley

615.343.3852

Antimicrobial Compounds and Methods of Use Thereof

Vanderbilt researchers, led by Eric Skaar, Ph.D., have identified novel compounds that are antimicrobial. These compounds represent a first in class as they target a new bacterial pathway that has never been targeted as an antimicrobial strategy.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

Assay for Novel Serotonin Transporter Blockers

The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.


Licensing Contact

Karen Rufus

615.322.4295